Navigation Links
Dendreon to Host Conference Call on August 3, 2011 to Announce Second Quarter 2011 Financial Results
Date:7/8/2011

SEATTLE, July 8, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Wednesday, August 3, 2011 at 4:30 p.m. ET to review the second quarter 2011 financial results.  Access to the discussion may be obtained as follows: Time:

4:30 PM ET / 1:30 PM PTDate:

August 3, 2011Dial-in:

1- 877-548-9590 (domestic) or +1-720-545-0037 (international);conference pass code: 82447836Webcast:

www.dendreon.com (homepage and investor relations section) A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-642-1687 or +1-706-645-9291 for international callers; the conference ID number is 82447836. The replay will be available from 7:30 pm ET on August 3 until 11:59 pm ET on August 10.  In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.About DendreonDendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010.  Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
2. FDA Approves Dendreons Los Angeles Cancer Immunotherapy Manufacturing Facility
3. Dendreon Announces Webcast Presentation at NASDAQ OMX 26th Investor Program
4. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner
5. Dendreon Announces Webcast Presentation at Upcoming Conferences
6. Dendreon Reports First Quarter 2011 Financial Results
7. Dendreon to Host Conference Call on May 2, 2011 to Announce First Quarter 2011 Financial Results
8. Dendreon Reports Fourth Quarter and 2010 Year End Financial Results
9. Dendreon Announces Webcast Presentations at Four Upcoming Conferences
10. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
11. Dendreon to Host Conference Call on March 1st to Announce Fourth Quarter and Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... 2017 According to a report by Transparency ... fragmented due to the presence of a large pool of participants; ... Fisher , and Sigma-Aldrich, compete with each other in this market. ... more than 76% of this market in 2016.  ... As of now, a large number ...
(Date:3/22/2017)... , March 22, 2017 Regeneron Pharmaceuticals, Inc. ... Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate ... U.K. Biobank resource. The initiative will enable researchers to gain ... medicines for a wide range of serious and life threatening ... ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017 ... announced that it has eclipsed the 130 million covered ... Cross Blue Shield of Texas . ... stages, the Company continues to enjoy strong payor acceptance ... of its clinical programs and genetic counseling, its industry-leading ...
Breaking Biology Technology:
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics ... ...
(Date:3/9/2017)... FRANCISCO and MOUNTAIN VIEW, Calif. ... , "Eating Well Made Simple," and 23andMe , ... help guide better food choices.  Zipongo can now provide ... their food preferences, health goals and biometrics, but also ... certain food choices. Zipongo,s personalized food decision ...
(Date:3/2/2017)... , March 2, 2017 Summary ... better understand Merck KGaA and its partnering interests and ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
Breaking Biology News(10 mins):